Prof. Jun Liang 梁军
Chief Physician, Professor
Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of malignant tumors, with a focus on medical diagnosis and treatment of gastrointestinal cancers.
Dr. Liang holds an MD and serves as Professor and Chief Physician. Current roles include Executive Deputy Director of the International Department and Deputy Director of Internal Medicine at Peking University Cancer Hospital. Dr. Liang has extensive experience in medical oncology for gastrointestinal tumors, leads multiple National Natural Science Foundation projects, and has published over 20 SCI articles in the past three years.
Professional roles
- Vice Chair, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair and Deputy Leader, CSCO Liver Cancer Expert Committee
- Member, American Society of Clinical Oncology
- Editorial Board Member, The Oncologist
Name order: in Chinese the family name comes first (Liang Jun). Papers usually list the name as Jun Liang or Liang J.
Selected publications
59 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Gastroenterol, 2024 (senior author): ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma. PubMed 38166741
- Cell Rep Med, 2023 (senior author): Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma. PubMed 37939712
- Lipids Health Dis, 2022 (senior author): Characterization of a lipid droplet and endoplasmic reticulum stress related gene risk signature to evaluate the clinical and biological value in hepatocellular carcinoma. PubMed 36581927
- J Hepatocell Carcinoma, 2022 (senior author): Lipid-Based Factors: A Promising New Biomarker for Predicting Prognosis and Conditional Survival Probability in Hepatocellular Carcinoma. PubMed 36051861
- Mol Cancer, 2022 (senior author): CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma. PubMed 34983546
- J Cancer Res Ther, 2021 (senior author): Prognostic nomograms for patients undergoing radical operation for stage I-III appendiceal adenocarcinoma: A surveillance, epidemiology, and end results database analysis. PubMed 35381736
- Cancer Manag Res, 2021 (senior author): Fibrinogen-Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy. PubMed 34079370
- Cost Eff Resour Alloc, 2018 (senior author): Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. PubMed 30087583
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion